Wikipedia:Articles for deletion/MUGEN NoE


 * The following discussion is an archived debate of the proposed deletion of the article below. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review).  No further edits should be made to this page.  

The result was delete Proto ::  type  10:51, 1 December 2006 (UTC)

MUGEN NoE


Tagged WP:CSD A7, but not an obvious delete so I'm bringing it here. Not sure if it's significant or not, I guess it may be a case of come back when there is more external coverage, I don't know. Guy (Help!) 23:11, 23 November 2006 (UTC)
 * delete - Not enough notable. There are a huge list of consortia of the various of the european research framework programmes. Consortia are per se  not notable. The results are maybe relevant in the relevant wiki-article. -- Cate 18:49, 27 November 2006 (UTC)


 * keep it Please note that this consortium has done a significant scientific work. Please check the publication list of the MUGEN participating people at, there are 473 original research articles in high impact journals such us Nature & Science,  Thanks User:Afantitis


 * Comment 1: You should write *Keep - Your comments... . ~, see How to discuss an AfD for more infos. This is a discussion to find if the article should be deleted or not, so I reccomend you to write your motivations. (and for personal comments, please use my talk page). Later I will comment on your comment, but I hope that administrators will extend the discussion period. Cate 08:52, 29 November 2006 (UTC)


 * Reasons for keep it
 * the MUGEN network of Excellence aims to structure and shape a world-class framework of European scientific and technological excellence in the field of “murine models for immunological disease”, to advance understanding of the genetic basis of disease and to enhance innovation and translatability of research efforts. MUGEN’s specific mission is to bring together different expertise from academic and industrial laboratories in order to study human immunological disease by integrating the participant institutions’ strengths in immunological knowledge with new approaches in functional genomics. By removing barriers to progress and promoting the synergistic interaction of scientists from various disciplines integrated, MUGEN expects to bring Europe a competitive advantage in the development of new diagnostic and therapeutic tools.


 * MUGEN aims to:


 * 1.        Systematically study animal models for immune diseases and processes through the application of functional genomic platforms (transgenesis, targeted and random mutagenesis, expression profiling and bioinformatics).


 * 2.        Integrate the outstanding research experience and capacities of each network participant to allow the efficient application of post-genomic approaches to generate new knowledge in immunological diseases and processes. Such knowledge is expected to lead to novel diagnostic and therapeutic tools.


 * 3.        Ensure spreading of excellence, optimal use and dissemination of the knowledge generated through the network beyond the boundaries of MUGEN, by integrating competencies to train researchers, to encourage knowledge transfer, to address innovation related aspects of research and to raise the public awareness of scientific research issues.


 * user Afantitis
 * The above discussion is preserved as an archive of the debate. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review). No further edits should be made to this page.